Johnson & Johnson (JNJ) EBIT (2009 - 2026)

Johnson & Johnson has disclosed EBIT across 18 years of filings, most recently posting $6.4 billion for Q1 2026.

• EBIT for Q1 2026 came in at $6.4 billion, up 2.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $40.1 billion (up 88.39% YoY), and the FY2025 annual result was $39.9 billion, up 89.98% from the prior year.
• EBIT came in at $6.4 billion for Q1 2026 at Johnson & Johnson, down from $20.1 billion in the prior quarter.
• In the past five years, EBIT ranged from a high of $20.1 billion in Q4 2025 to a low of $3.6 billion in Q4 2024.
• The 5-year median for EBIT is $5.9 billion (2024), against an average of $7.4 billion.
• Across the five-year window, EBIT sank 80.91% in 2024 and soared 457.46% in 2025, its largest moves.
• Johnson & Johnson's EBIT stood at $5.3 billion in 2022, then jumped by 255.78% to $18.9 billion in 2023, then tumbled by 80.91% to $3.6 billion in 2024, then jumped by 457.46% to $20.1 billion in 2025, then tumbled by 68.28% to $6.4 billion in 2026.
• The last three EBIT figures came in at $6.4 billion (Q1 2026), $20.1 billion (Q4 2025), and $7.0 billion (Q3 2025), per Business Quant data.